Preliminary antitumor exercise of DBPR112 in people with solid tumors [ Time Body: The tumor responses had been gathered from your time of the primary dose of investigational products until thirty times following the past dose of investigational solution administration. ]Additionally, therapy with DB2313 enhanced survival and minimized tumor st